A 3-year gold-standard, randomised, placebo-controlled, double-blind clinical trial investigating the efficacy of the BioxyQuell wound treatment system has been published in Journal of Wound Care.
The study was conducted in primary care through four Hampshire-based GP surgeries, providing a “real world” assessment of the technology.
Patients suffering with chronic, static, non-healing venous leg ulcers (VLUs) were treated with either a 20 part per million aqueous oxygen peroxide (AOP) solution or a sterile water placebo.
Patients received six fifteen minute treatments over a period of two weeks, with follow-up observations over 12 months. Patients were blind to the treatment they received as were assessing clinicians.
The results of the study identified statistically significant differences in wound size reduction, reduction in microbiological organisms, reduction in pain and long term healing outcomes, all in favour of AOP treatment.
Patients treated with AOP were statistically less likely to develop an infected wound than patients treated with the placebo. Investigators found that 100% of patients treated with AOP and who successfully completed the study healed within 12 months, compared to 53% of placebo patients. Patients also reported large reductions in pain during the two week period of AOP treatment.
For more information visit the Journal of Wound Care web site.